GLYX13

CAS No.	117928-94-6	Cat. No.	BCP09863
Name	GLYX13
Synonyms	GLYX-13;GLYX 13;Rapastinel; BV-102; BV102; BV 102; TPPT-amide; Thr-Pro-Pro-Thr-NH2;
Formula	C18H31N5O6	M. Wt	413.47

Description	GLYX-13, also known as Rapastinel and BV-102, is a novel antidepressant drug approved as an adjunctive therapy for the treatment of treatment-resistant major depressive disorder. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) that acts as a selective, weak partial agonist (mixed antagonist/agonist) of an allosteric site at the glycine site of the NMDA receptor complex (Emax ≈ 25%).[1][2] The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to both inhibit and enhance NMDA receptor-mediated signal transduction.
Pathways	Ion Channel/Membrane Transporter
Targets	AMPA/NMDA

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.